Waldencast plc is classed by the SEC under Perfumes, Cosmetics & Other Toilet Preparations (industry code 2844), based in London, GB. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $272 million and a loss of $248 million (its filed statements).
Product businessPerfumes, Cosmetics & Other Toilet PreparationsLondon, GBfilings since 20218 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2844, Perfumes, Cosmetics & Other Toilet Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 3.4 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.1 out of ten, present 3.4 out of ten, future 3.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 1.9 out of ten. 5 warning events since 2021; the latest 2023-05-02. 19th percentile among 18 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.2 out of ten. +23.6% a year over 5 filed years; profitable in 0 of 5. 52nd percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 0.3 out of ten. CrossAssetData estimate 0.3/10, confidence 35 of 100 (one part). 3rd percentile among 16 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 2.9 out of ten. ROE -50%: lost 50¢ per shareholder dollar. Leverage 38%: owes 38¢ per asset dollar. 29th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.3 out of ten. bottom 43% of 17 in its family; net margin -84.4%. 43rd percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 3.3 out of ten. bottom 33% of 10 in its family for leadership; chief executive since 2021. 33rd percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 4.8 out of ten. bottom 48% of 17 in its family for room to expand. 48th percentile among 17 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 4.2 out of ten. bottom 42% of 16 in its family for growth drivers. 42nd percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 0.5 out of ten. bottom 5% of 16 in its family for expectations against reality. 5th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-03-13 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2022-05-16 for the period ended 2022-03-31 (on EDGAR). Newest filing: Form POS AM, 2026-10-09. Filings on record since 2021. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Obagi Skincare 59%, Milk Makeup 41%. As tagged in its annual report (Form 20-F, filed 2026-03-13).
Who runs it
Brousset, Michel (Chief Executive Officer); Manfredi, Manuel (Chief Financial Officer); Sebti, Hind (Chief Growth Officer); Souza, Cristiano (director); Brookie, Kelly (director); Chatterley, Aaron (director); Dutra, Felipe (director); Hickman, Juliette (director); Thompson, Motta Roberto Moses (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.